Toward a More Physiologic State: The Use of Human Ultralente and the "Run and Shoot" Plan

Abstract

Get full access to this article

View all access options for this article.

References

Usala AL , Blumer Jlb. Pharmacology of new hormonal therapies in the treatment of pediatric endocrine disorders. Ped Clin of North Am 1989;36:1157-82.

Galloway JA , Root MA , Bergstrom CT , et al. Clinical pharmacologic studies with human insulin (recombinant DNA). Diabetes Care 1982;5(suppl 2):13.

Kemmer FW , Sonnenberg G. , Cuppers HJ , et al. Absorption kinetics of semisynthetic human insulin and biosynthetic (recombinant DNA) human insulin. Diabetes Care 1982;5(suppl2):23.

Bottermann P. , Gyraram H. , Wahl K. , et al. Insulin concentrations and time-action profiles of three different intermediate acting insulin preparations in non-diabetic volunteers under glucose-controlled glucose infusion technique . Diabetes Care 1982;5(suppl 2):32.

Marre M. , Tabbi-Anneni A. , Tabbi-Anneni H. , et al. Comparative study of NPH human insulin (recombinant DNA) and NPH bovine insulin in diabetic subjects. Diabetes Care 1982;5(suppl 2):63.

Sonnenberg GE , Kemmer FW , Cuppers HJ , et al. Subcutaneous use of regular human insulin (Novo): pharmacokinetics and continuous insulin infusion therapy. Diabetes Care 1983;6(suppl 1):35.

Gulan M. , Gottesman IS , Zinman B. Biosynthetic human insulin improves postprandial glucose excursions in type I diabetes. Ann Int Med 1987;107:506.

Home PD, Alberti KGMM. The new insulins—their characteristics and clinical indications. Drugs 1983;24:401.

Physician's Desk Reference, 46th ed. Montvale, NJ: Medical Economics Company Inc, 1992:1626.

10.

Wolfsdorf JI , Laffell Lmb , Pasquarello C. , Vernon A. , Herskowitz RD Split mixed insulin regimen with human ultralente before supper and NPH (Isophane) before breakfast in children and adolescents with IDDM. Diabetes Care 1991;14:1100-6.

11.

American Diabetes Association. Diabetes Ato Z. Alexandria, Va: American Diabetes Association, 1988:9.